Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia

Bibliography

• Hughes WT, Armstrong D, Bodey GP, Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;12:1323-32
   Google Scholar
• Rubin RH, Ferraro MJ. Understanding and diagnosing infectious complications in the immunocompromised host. Current issues and trends. Hematol Oncol Clin North Am 1993;7:795-812
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Available from: http://ctep.cancer.gov [Last assessed 1 August 2010]
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51
   PubMed Web of Science ®Google Scholar
• Leonard RC, Miles D, Thomas R, Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-8
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, Levofloxacin to prevent bacterial infections in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98
   PubMed Web of Science ®Google Scholar
• Blay JY, Chauvin F, Le Cesne A, Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996;14:636-43
   Google Scholar
• Voog E, Bienvenu J, Warzocha K, Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000;18:325-31
   PubMed Web of Science ®Google Scholar
• Wunderlich A, Kloess M, Reiser M, Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881-93
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-31
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37
   PubMed Web of Science ®Google Scholar
• Dale DC, McCarter GC, Crawford J, Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. JNCCN 2003;1:440-54
   Google Scholar
• Leong DC, Kinlay S, Ackland S, Low-risk febrile neutropenia in a medical oncology unit. Aust N Z J Med 1997;27:403-7
   PubMedGoogle Scholar
• Lyman GH, Dale DC, Friedberg J, Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-11
   PubMed Web of Science ®Google Scholar
• Szucs TD, Leonard R, Pettengell R, Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer chemotherapy. Support Care Cancer 2006;14:901-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 1999;18:539-44
   PubMed Web of Science ®Google Scholar
• Aslani A, Smith RC, Allen BJ, The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796-803
   PubMed Web of Science ®Google Scholar
• Silber JH, Fridman M, DiPaola RS, First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998;16:2392-400
   PubMed Web of Science ®Google Scholar
• Blay JY, Chauvin F, Le Cesne A, Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996;14:636-43
   Google Scholar
• Elting LS, Rubenstein EB, Rolston KVI, Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;5:247-59
   Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;16:3038-51
   Google Scholar
• Crawford J, Ozer H, Stoller R, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Crawford J. Neutrophil growth factors. Curr Hematol Rep 2002;1:95-102
   PubMedGoogle Scholar
• Aapro MS, Cameron DA, Pettengell R, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-05
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (2010) Practice Guidelines in Oncology v.1.2010. Myeloid Growth Factors. Available from: www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. [Last accessed 11 November 2010]
   Google Scholar
• Ozer H, Armitage JO, Bennett CL, Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American society of clinical oncology growth factors expert panel. J Clin Oncol 2000;18:3558-85
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Boo TM, Smit HJ, Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974-84
   PubMed Web of Science ®Google Scholar
• Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 2008;113:945-55
   PubMed Web of Science ®Google Scholar
• Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol 2008;35:221-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, Herpen C, Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704
   PubMed Web of Science ®Google Scholar
• Repetto L, Biganzoli L, Koehne CH, EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:2264-72
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Kuderer NM, Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109-18
   PubMedGoogle Scholar
• Balducci L, Al-Halawani H, Charu V, Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416-24
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Alibhai SM, Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-11
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189
   Google Scholar
• Dubois RW, Pinto LA, Bernal M, Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Supportive Cancer Ther 2004;2(1):34-41
   PubMedGoogle Scholar
• Mey UJ, Maier A, Schmidt-Wolf IG, Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007;15:877-84
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402-7
   PubMed Web of Science ®Google Scholar
• Minckwitz G, Kümmel S, Bois A, Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:292-8
   PubMed Web of Science ®Google Scholar
• Minckwitz G, Schwenkglenks M, Skacel T, Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 2009;45:608-17
   PubMed Web of Science ®Google Scholar
• Amgen (2008) Neulasta Summary of Product Characteristics. Available from: www.ema.europa.eu/humandocs/PDFs/EPAR/neulasta/emea-combined-h420en.pdf. [Last accessed 11 November 2010]
   Google Scholar
• Amgen (2009) Neupogen summary of product characteristics. Available from: http://emc.medicines.org.uk/medicine/7907/SPC/Neupogen+30MU+and+48MU+Vials+and+Singleject+Syringes/. [Last accessed 11 November 2010]
   Google Scholar
• Yang BB, Hill R, Hollifield A, Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of 6 clinical trials in a variety of cancer populations. Blood 2003;102: Abstract 1918
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Andreopoulou E, Tolis CF, G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001;91:909-17
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte—colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer 2004;101:1767-75
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Wolff DA, Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:2917-24
   Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Int Med 2005;142:979-95
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Cullen MH, Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1743-51
   PubMed Web of Science ®Google Scholar
• Razonable RR, Litzow MR, Khaliq Y, Bacteraemia due to Viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:1469-74
   PubMed Web of Science ®Google Scholar
• Kern WV, Klose K, Jellen-Ritter AS. Fluoroquinolone resistance of Escherichia coli at a cancer centre: epidemiological evolution and effects of discontinuing and re-introducing quinolone use in neutropenic patients with leukaemia. Eur J Clin Microbiol Infec Dis 2005;24:111-18
   PubMed Web of Science ®Google Scholar
• Segal BH, Freifeld AG, Baden LR, Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122-74
   PubMedGoogle Scholar
• Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect 2001;42:120-5
   PubMed Web of Science ®Google Scholar
• Chan S, Friedrichs K, Noel D, Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54
   PubMed Web of Science ®Google Scholar
• Mermel LA, Farr BM, Sherertz RJ, IDSA guidelines for the management of intravascular catheter-related infections-I. Clin Infect Dis 2001;32:1249
   PubMed Web of Science ®Google Scholar
• Hubel K, Hegener K, Schnell R, Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999;78(2):73-7
   PubMed Web of Science ®Google Scholar
• Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145(9):1621-9
   PubMedGoogle Scholar
• Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103:1103-13
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36(9):1103-10
   PubMed Web of Science ®Google Scholar
• Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40(Suppl 4):S246-52
   PubMed Web of Science ®Google Scholar
• Mathur P, Chaudhry R, Kumar L, A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes. Med Oncol 2002;19:267-72
   PubMed Web of Science ®Google Scholar
• Sugar AM. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use. Arch Intern Med 1990;150:2258-64
   PubMed Web of Science ®Google Scholar
• Malik IA, Khan WA, Karim M, Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31
   PubMed Web of Science ®Google Scholar
• Moores KG. Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am J Health Syst Pharm 2007;64:717-22
   PubMed Web of Science ®Google Scholar
• Cometta A, Caladra T, Gaya H, Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-15
   PubMed Web of Science ®Google Scholar
• Karthaus M, Wolf HH, Kampfe D, Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998;44:343-54
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Hathorn JW, Hiemenz J, A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315(9):552-8
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T, A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11
   PubMed Web of Science ®Google Scholar
• Kern WV, Cometta A, De Bock R, Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341:312-18
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Samonis G, Chrysanthopoulou SA, Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5(7):431-9
   PubMed Web of Science ®Google Scholar
• Paul M, Borok S, Fraser A, Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005;(3):CD003914
   Google Scholar
• Dompeling EC, Donnelly JP, Deresinski SC, Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996;32A(8):1332-9
   PubMed Web of Science ®Google Scholar
• Freifeld A, Baden L, Brown A, Fever and neutropenia. J Natl Compr Canc Netw 2004;2:391
   Google Scholar
• Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: current status. Curr Top Med Mycol 1997;8(1-2):5-14
   PubMedGoogle Scholar
• Walsh TJ, Pappas P, Winston DJ, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-34
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391-402
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Maertens J, Meersseman W, Van Bleyenbergh P. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009;22:183-90
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23(18):4198-214
   PubMed Web of Science ®Google Scholar
• Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101(Suppl 1):S18-22
   Google Scholar